Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Common

Stock

Stock

Stock

11/26/2014

11/26/2014

11/26/2014

December 01, 2014

December 0	1, 2014									
FORM	ЛΔ							OMB AF	PPROVAL	
	Washington, D.C. 20549						OMB Number:	3235-0287		
Check the character of	ger so STATEN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires: January 31, 2005 Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
			Issuer Name and bol RTEX PHAR C / MA [VRT	MACEU			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		(Mor 11/2	ate of Earliest T nth/Day/Year) 26/2014	ransaction			X Director Officer (give to below)		Owner or (specify	
	(Street)	Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BOSTON,	MA 02210						Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Table I - Non-I	Derivative	Secui	rities Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Ye	Code	4. Securi on(A) or Di (Instr. 3,	sposed	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/26/2014		M	4,800	A	\$ 10.41	343,695	D		

M

M

 $S_{\underline{(1)}}$

1,300 A \$ 17.16 344,995

4,400 A \$ 35.64 349,395

\$

114.42

340,344

9,051 D

D

D

D

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

					(2) (3)				
Common Stock	11/26/2014	S(1)	1,449	D	\$ 115.28 (3) (4)	338,895	D		
Common Stock						13,286	I	401(k)	
Common Stock						172,589	I	Common Stock held in trust (5)	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.									
				natio	are not n	SEC 1474 (9-02)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 10.41	11/26/2014		M	4,800	<u>(6)</u>	02/02/2015	Common Stock	4,800
Stock Option (right to buy)	\$ 17.16	11/26/2014		M	1,300	<u>(6)</u>	07/19/2015	Common Stock	1,300
Stock Option (right to buy)	\$ 35.64	11/26/2014		M	4,400	<u>(6)</u>	02/01/2016	Common Stock	4,400

De Sec (In

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BOGER JOSHUA S C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210



Signatures

Omar White, Attorney-In-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$114.42 (range \$113.96 to \$114.95).
- (3) Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$115.28 (range \$114.99 to \$115.77).
- (5) Common stock held in grantor retained annuity trusts.
- (6) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3